Atlantic Equities analyst Steve Chesney maintains AbbVie (NYSE:ABBV) with a Neutral and lowers the price target from $178 to $162.
Atlantic Equities Maintains Neutral on AbbVie, Lowers Price Target to $162
Atlantic Equities analyst Steve Chesney maintains AbbVie (NYSE:ABBV) with a Neutral and lowers the price target from $178 to $162.
Related Posts
As France Extends Its Medical Marijuana Trial, Aurora And Ethypharm Continue To Be Its Exclusive Suppliers
Aurora Europe GmbH, a subsidiary of Aurora Cannabis Inc.
Stratasys Announces Channel Partnership With Adroitec Information Systems Pvt. Ltd.
Stratasys Ltd. (NASDAQ:SSYS), a leader in polymer 3D printing solutions, announced that Adroitec Information Systems Pvt. Ltd., a global engineering solutions provider with state-of-the-art development centres
4 Analysts Have This to Say About Vital Farms
Analysts have provided the following ratings for Vital Farms (NASDAQ:VITL) within the last quarter: